Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.48
-0.32 (-0.41%)
Streaming Delayed Price
Updated: 3:27 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
53
54
Next >
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
July 03, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...
Via
Benzinga
AstraZeneca Unusual Options Activity
July 03, 2023
Via
Benzinga
AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment
July 03, 2023
The company tested a treatment in combination with Daiichi Sankyo.
Via
Investor's Business Daily
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
July 03, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...
Via
Benzinga
AstraZeneca Unusual Options Activity For June 28
June 28, 2023
Via
Benzinga
Price Over Earnings Overview: AstraZeneca
June 27, 2023
Via
Benzinga
Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company
June 24, 2023
Deals, financings, trials and approvals for the week ending June 23.
Via
Talk Markets
4 Unparalleled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
July 01, 2023
Bargains abound with the innovation-driven Nasdaq Composite still well below its all-time high.
Via
The Motley Fool
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
June 29, 2023
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)...
Via
Benzinga
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial
June 29, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
June 28, 2023
From
AstraZeneca
Via
Business Wire
This Is What Whales Are Betting On AstraZeneca
June 23, 2023
Via
Benzinga
Is AstraZeneca a Top Stock to Buy Right Now?
June 22, 2023
The pharma specialist's top-shelf clinical pipeline and product portfolio should be tremendous growth drivers in the years ahead.
Via
The Motley Fool
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
June 26, 2023
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks.
Via
Talk Markets
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
June 26, 2023
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other...
Via
Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
June 26, 2023
The European Union has reco
Via
Benzinga
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
June 26, 2023
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t
Via
MarketBeat
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
June 21, 2023
Via
Benzinga
What Does AstraZeneca's Debt Look Like?
June 21, 2023
Via
Benzinga
2 Best Biotech Stocks to Buy Right Now
June 16, 2023
These international-based pharmaceutical companies pay market-topping dividends to shareholders.
Via
The Motley Fool
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
June 23, 2023
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a
Via
Benzinga
AI Stocks: C3.ai, Palantir Pull Back Amid HPE, Cybersecurity, Cloud AI News
June 23, 2023
The big rally in AI stocks may finally be taking a break but the steady drumbeat in artificial intelligence news continues.
Via
Investor's Business Daily
European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide
June 22, 2023
The EU's drugs watchdog, the European Medicines Agency, recently raised a thyroid cancer safety signal for Novo Nordisk A/S (NYSE: NVO) drugs, including the much talked semaglutide used i
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
Why Are Pieris Pharmaceuticals Shares Tanking Today
June 21, 2023
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4...
Via
Benzinga
Spotify to Launch New Expensive Subscription Plan, Chinese Vendors Bypass US Embargo to Supply Nvidia AI Chips, Eddie Wu To Succeed Daniel Zhang As Alibaba's CEO: Today's Top Stories
June 20, 2023
Bloomberg
Via
Benzinga
AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions
June 20, 2023
European drugmaker AstraZeneca plc (NASDAQ: AZN) is reportedly drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is considered an option amid mounting...
Via
Benzinga
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
June 17, 2023
Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates...
Via
Talk Markets
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
June 14, 2023
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
53
54
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.